Hematology, Oncology & Immunology · Topic 18 of 26

Acute Leukemia Presentation

Hematology-oncology · acute leukemia

Acute Leukemia Presentation

Pancytopenia with circulating blasts is acute leukemia until the marrow proves otherwise — and suspected APL gets ATRA and blood products before the genetics return.

Key numbers

Acute leukemia: 20% or more blastsblasts ≥ 20%

Transfuse APL to platelet and fibrinogen targetsplt>30–50k fib>100–150

01 · Defined byAcute leukemia: 20% or more blasts

Pancytopenia with circulating blasts suggests acute leukemia; diagnosis needs bone marrow with ≥ 20% blasts (≥ 10% under the ICC when an AML-defining lesion such as PML::RARA is present). Fewer blasts suggest myelodysplasia.

02 · DoSuspected APL: start ATRA immediately

Give ATRA (tretinoin) at the first suspicion of acute promyelocytic leukemia, before genetic confirmation: about a third of registry patients die within 30 days, many before any ATRA. ATRA corrects the DIC in 2–5 days.

03 · DoTransfuse APL to platelet and fibrinogen targets

Support APL coagulopathy from suspicion until it resolves: platelets above 30,000–50,000/µL, fibrinogen above 100–150 mg/dL (cryoprecipitate or fibrinogen) and INR below 1.5 (plasma), checked at least daily; avoid central lines, lumbar puncture and leukapheresis.

Causes & risk factors

Why it happens

ALL seeds the CNS: intrathecal prophylaxisALL commonly infiltrates the meninges (and testes), so every ALL regimen includes CNS prophylaxis with intrathecal methotrexate, cytarabine and/or hydrocortisone; CNS involvement is rare in AML.

Philadelphia-positive ALL gets a tyrosine kinase inhibitort(9;22) (Philadelphia chromosome, BCR::ABL1) is a common lesion in adult ALL; Ph-positive ALL is treated with a tyrosine kinase inhibitor (imatinib, dasatinib) plus steroids with or without chemotherapy.

Presentation

What you'll see

Presents with anemia, bleeding and infection must knowSymptoms come from marrow failure over days to weeks: anemia (fatigue, dyspnea, pallor), thrombocytopenia (petechiae, epistaxis, gum bleeding, occasionally intracranial hemorrhage) and neutropenia (fever, severe or recurrent infection).

APL presents with DIC and bleeding must knowAPL (10–15% of AML; t(15;17) PML::RARA; patients younger than in other AML) presents with DIC in about three-quarters — prolonged PT and PTT, high D-dimer, low fibrinogen, thrombocytopenia — risking fatal intracranial or pulmonary hemorrhage.

Diagnosis & monitoring

Work-up

Arsenic trioxide: watch QTc, K⁺ and Mg²⁺Arsenic trioxide prolongs the QTc (over 500 ms in 40% of early-trial patients): check ECGs at least weekly, keep potassium above 4 mEq/L and magnesium above 1.8 mg/dL, and stop other QT-prolonging drugs.

Do right now

In this order

First moves

Suspected APL: start ATRA immediately

→

Transfuse APL to platelet and fibrinogen targetsplt>30–50k fib>100–150

→

Order the emergency work-up at diagnosis

→

Neutropenic fever: cultures, then antipseudomonal β-lactam

Why each step

Suspected APL: start ATRA immediatelyGive ATRA (tretinoin) at the first suspicion of acute promyelocytic leukemia, before genetic confirmation: about a third of registry patients die within 30 days, many before any ATRA. ATRA corrects the DIC in 2–5 days.

Transfuse APL to platelet and fibrinogen targetsSupport APL coagulopathy from suspicion until it resolves: platelets above 30,000–50,000/µL, fibrinogen above 100–150 mg/dL (cryoprecipitate or fibrinogen) and INR below 1.5 (plasma), checked at least daily; avoid central lines, lumbar puncture and leukapheresis.

Order the emergency work-up at diagnosisAt diagnosis order coagulation studies with fibrinogen (DIC), chemistry with creatinine, uric acid and LDH (tumor lysis), cultures if febrile, head CT for neurologic signs, and an echocardiogram or MUGA before anthracyclines.

Neutropenic fever: cultures, then antipseudomonal β-lactamFever with an ANC below 500/µL needs blood cultures and an antipseudomonal β-lactam (cefepime, piperacillin-tazobactam or meropenem) within 1 hour; persistent fever despite antibiotics prompts chest CT and empiric antifungal therapy (see Neutropenic Fever).

Management

Orders

ATRA plus arsenic cures standard-risk APLStandard-risk APL (WBC ≤ 10,000/µL) is treated with ATRA plus arsenic trioxide without cytotoxic chemotherapy, with over 90% cure; WBC above 10,000/µL is high risk and adds idarubicin or gemtuzumab ozogamicin.

Prophylactic platelets below 10,000/µLSupportive transfusion: prophylactic platelets when the count falls below 10,000/µL (higher with bleeding or APL), and packed red cells for hemoglobin below 7–8 g/dL.

Red flags & don'ts

Avoid harm

Differentiation syndrome: dexamethasone 10 mg every 12 hours complicationDifferentiation syndrome (days to weeks into ATRA or arsenic): dyspnea, pulmonary infiltrates, effusions, fever, weight gain, edema, hypotension, AKI. Give dexamethasone 10 mg IV every 12 hours; hold arsenic, and ATRA if severe.

Prevent tumor lysis before induction complicationRapid leukemic cell turnover and induction cause tumor lysis (hyperuricemia, hyperphosphatemia, hypocalcemia, hyperkalemia): give IV hydration with allopurinol or rasburicase before and during induction (see Tumor Lysis Syndrome).

WBC over 100,000 risks leukostasis complicationA blast count above 100,000/µL with hypoxemia, pulmonary infiltrates or neurologic signs is leukostasis — an emergency needing urgent cytoreduction (see Hyperviscosity & Leukostasis).

AML or ALL?

Commonly confused

Typical patient	Adults; median age 68
Blast markers	Myeloperoxidase-positive; Auer rods
CNS involvement	Rare
Genetic lesion to act on	PML::RARA (APL): ATRA now

More detail

Reference

Show 7 reference facts

Myeloid sarcoma — extramedullary AML infiltration of skin (leukemia cutis), gingiva and mucosa — occurs in a minority; leukemic infiltration can also enlarge the liver, spleen and nodes and cause bone pain.

AML is the most common acute leukemia in adults (median age 68); ALL is the most common childhood cancer and about 20% of adult acute leukemias.

Standard AML induction for fit patients is 7 + 3 — continuous-infusion cytarabine for 7 days plus daunorubicin or idarubicin for 3 days — with profound myelosuppression afterward.

Older or frail patients with AML usually receive less intensive therapy, such as venetoclax with azacitidine or decitabine, which improves remission and survival over azacitidine alone.

Complete remission is under 5% marrow blasts, ANC above 1,000/µL, platelets above 100,000/µL and transfusion independence.

A leukemoid reaction (neutrophils above 50,000/µL from infection or another cancer) never shows a high blast count, which separates it from acute leukemia.

Therapy-related AML follows alkylating agents (mean latency 5–7 years) or topoisomerase II inhibitors (6 months to 3 years); radiation, benzene, MDS and Down syndrome also raise risk.

Pearl

In APL the killer is bleeding, not the leukemia: ATRA on suspicion, products to targets, no needles you can avoid.

Sources · Merck Manual Professional — Acute Myeloid Leukemia (AML) (2026) · Merck Manual Professional — Acute Lymphoblastic Leukemia (ALL) · Merck Manual Professional — Overview of Leukemia (2026) · Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J 2021;11:123 · Trisenox (arsenic trioxide) prescribing information — DailyMed · Ali AM et al. Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest. Hematol Oncol 2016;34:69–78 · Merck Manual Professional — Management of Adverse Effects of Cancer Therapy · Sanz MA et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 2019;133:1630–1643 · Freifeld AG et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the IDSA. Clin Infect Dis 2011;52(4):e56–e93 · Starter sheet built from the verified AGACNP fact map (facts reviewed 2026-10-15).